From: A phase I study of the safety and activity of K-001 in patients with advanced pancreatic ductal adenocarcinoma
Cohort
A
B
C
D
Incremental percent
Starting dose
20%
17%
14%
Dose level
2700 mg/day
(1350 mg BID)
3240 mg/day
(1620 mg BID)
3780 mg/day
(1890 mg BID)
4320 mg/day
(2160 mg BID)
Number of patient
3